ciltacabtagene autoleucel
janssen,legend biotech
['multiple myeloma', 'carvykti', 'legn', '$jnj']
carvykti maintains response rates at two years in multiple myeloma patients #asco22 $jnj $legn 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.